Drugs / AstroStem-V
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04486001 | Dec 2020 → Jun 2021 | COVID-19 | Sorrento Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04527224 | Oct 2022 → Nov 2023 | pneumonia | Nature Cell Co. Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AstroStem-V | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04527224 ↗ |
| Known as | PSC-04 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04486001 ↗ |
| Modality | Cell therapy | “PSC-04, an adipose-derived allogeneic mesenchymal stem cell” NCT04486001 ↗ |
| Route | Intravenous | “Primary: To evaluate the safety of intravenous infusion of allogeneic adipose stem cells in patients with COVID-19 disease and respiratory distress.” NCT04486001 ↗ |